GW Pharmaceuticals PLC (GWPH) Upgraded to “Strong-Buy” at Vetr Inc.
GW Pharmaceuticals PLC (NASDAQ:GWPH) was upgraded by stock analysts at Vetr from a “buy” rating to a “strong-buy” rating in a report released on Tuesday. The brokerage presently has a $141.40 price target on the biopharmaceutical company’s stock. Vetr‘s price objective would indicate a potential upside of 12.93% from the stock’s current price.
GWPH has been the subject of a number of other research reports. Morgan Stanley upped their price target on GW Pharmaceuticals PLC from $152.00 to $160.00 and gave the stock an “overweight” rating in a report on Sunday, September 25th. Goldman Sachs Group Inc. initiated coverage on GW Pharmaceuticals PLC in a report on Friday, October 7th. They issued a “buy” rating and a $189.00 price target for the company. Leerink Swann initiated coverage on GW Pharmaceuticals PLC in a report on Tuesday, October 4th. They issued an “outperform” rating and a $162.00 price target for the company. Numis Securities Ltd raised GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Friday, August 26th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $147.00 target price on shares of GW Pharmaceuticals PLC in a report on Monday, September 26th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $143.40.
Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) traded down 1.31% during trading on Tuesday, hitting $125.21. The stock had a trading volume of 359,535 shares. The firm’s 50-day moving average is $113.58 and its 200 day moving average is $93.44. GW Pharmaceuticals PLC has a 52-week low of $35.83 and a 52-week high of $137.88. The firm’s market cap is $2.74 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/18/gw-pharmaceuticals-plc-gwph-upgraded-to-strong-buy-at-vetr-inc.html
GW Pharmaceuticals PLC (NASDAQ:GWPH) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.21) by $1.15. The company earned $3.10 million during the quarter, compared to analysts’ expectations of $3.63 million. GW Pharmaceuticals PLC had a negative return on equity of 26.26% and a negative net margin of 409.40%. GW Pharmaceuticals PLC’s quarterly revenue was down 73.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.09) EPS. On average, analysts expect that GW Pharmaceuticals PLC will post ($4.52) EPS for the current year.
Large investors have recently bought and sold shares of the stock. Advisory Services Network LLC raised its stake in GW Pharmaceuticals PLC by 1,109.2% in the third quarter. Advisory Services Network LLC now owns 786 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 721 shares during the period. Seven Eight Capital LLC raised its position in shares of GW Pharmaceuticals PLC by 216.7% in the first quarter. Seven Eight Capital LLC now owns 1,900 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 1,300 shares during the last quarter. IFP Advisors Inc raised its position in shares of GW Pharmaceuticals PLC by 5.7% in the second quarter. IFP Advisors Inc now owns 1,859 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 100 shares during the last quarter. Rothschild Investment Corp IL acquired a new position in shares of GW Pharmaceuticals PLC during the second quarter valued at $200,000. Finally, HighTower Advisors LLC acquired a new position in shares of GW Pharmaceuticals PLC during the second quarter valued at $203,000. Institutional investors and hedge funds own 68.50% of the company’s stock.
About GW Pharmaceuticals PLC
GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.